Skip to main content

Table 2 Effects of clinically approved natural product antineoplastic agents and of cytochalasin congeners on drug-sensitive and multidrug-resistant human ovarian carcinoma lines

From: Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro

Cell line SKOV3a SKVCR0.015 SKVCR0.1 SKVLB1
IC concentrations (nM) at 96 h IC90 IC90 RI IC90 RI IC90 RI
Doxorubicin 11 125 11 125 11 2900 264
Paclitaxel 2.8 8 3 4 1.4 3900 1400
Vinblastine 1.9 10 5 20 10 3100 1600
Cytochalasin A 1000 1000 1 500 0.5 750 0.75
Cytochalasin B 2250 1500 0.67 1250 0.56 3000 1.33
21, 22-Dihydrocytochalasin B 3000 2400 0.8 1600 0.53 5000 2.5
21, 22-Dihydrocytochalasin B γ-L 40000 30000 0.75 30000 0.75 40000 1
Cytochalasin C 330 250 0.76 125 0.38 8000 24
Cytochalasin D 80 80 1 320 4 8000 100
Cytochalasin E 200 ND   ND   1600 8
Cytochalasin H 100 ND   ND   1600 16
Cytochalasin J 800 ND   ND   3200 4
  1. ND not determined, RI resistance index compared to parental SKOV3 line
  2. aRI = 1 for all agents for SKOV3 line